AML is an aggressive hematological malignancy with highest incidence in the older adults.
The adverse features of AML in the elderly, and the frailties and comorbidities frequently …

Combination regimens are a standard of care for many cancers. However, components of
such regimens are typically first developed individually and subsequently combined using …

Older patients with acute myeloid leukemia (AML) respond poorly to standard induction
therapy. B-cell lymphoma 2 (BCL-2) overexpression is implicated in survival of AML cells …

Background Clonal hematopoiesis of indeterminate potential (CHIP) is a novel
cardiovascular disease (CVD) risk factor in individuals without acute myeloid leukemia …

Acute myeloid leukemia (AML), with an incidence increasing with age, is the most common
acute leukemia in adults. Concurrent comorbidities, mild to severe organ dysfunctions, and …

Dementia and cancer occur commonly in older adults. Yet, little is known about the effect of
dementia on cancer treatment and outcomes in patients diagnosed with cancer, and no …

Objectives: A comorbid diagnosis of cancer and dementia (cancer–dementia) may have
unique implications for patient cancer-related experience. The objectives were to estimate …

Acute myeloid leukemia (AML) is a devastating disease, globally causing 85 000 deaths per
year in 2016, a number predicted to double in 2040, with years of life lost estimated to be 2.6 …

High proportion of patients with multiple myeloma suffer from comorbidities which may alter
clinical management. Therefore, our aims were to evaluate the prevalence of comorbidities …

To describe the prevalence of comorbidity and its impact on survival in newly diagnosed
multiple myeloma patients compared with population controls. Cases of newly diagnosed …